137 related articles for article (PubMed ID: 37655597)
21. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
23. Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost.
Chen KY; Bucci TG; Shaw JR; Alexander MD; Grgic T; Riches M; Ptachcinski JR
Transfus Apher Sci; 2022 Apr; 61(2):103303. PubMed ID: 34801430
[TBL] [Abstract][Full Text] [Related]
24. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Flomenberg N; Comenzo RL; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
[TBL] [Abstract][Full Text] [Related]
25. Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery.
Mehl J; Akhoundova D; Bacher U; Jeker B; Rhyner Agocs G; Ruefer A; Soltermann S; Soekler M; Winkler A; Daskalakis M; Pabst T
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791933
[TBL] [Abstract][Full Text] [Related]
26. Benefits of plerixafor for mobilization of peripheral blood stem cells prior to autologous transplantation: a dual-center retrospective cohort study.
Nakamura N; Jo T; Arai Y; Matsumoto M; Sakai T; Tsunemine H; Takaori-Kondo A; Arima N
Cytotherapy; 2023 Jul; 25(7):773-781. PubMed ID: 36914555
[TBL] [Abstract][Full Text] [Related]
27. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection.
Cashen AF; Rettig M; Gao F; Smith A; Abboud C; Stockerl-Goldstein K; Vij R; Uy G; Westervelt P; DiPersio J
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1282-1289. PubMed ID: 28476490
[TBL] [Abstract][Full Text] [Related]
29. Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.
Zhu J; Huang H; Chen H; Zhang X; Li Z; Wu D; Zhou D; Song Y; Hu Y; Liang Y; Ren H; Huang H; Li N; Chen H; Hu J; Li J; Meng R; Wu J; Yu D; Huang X
Transfusion; 2018 Jan; 58(1):81-87. PubMed ID: 29238988
[TBL] [Abstract][Full Text] [Related]
30. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
[TBL] [Abstract][Full Text] [Related]
31. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
Ji MM; Shen YG; Gong JC; Tang W; Xu XQ; Zheng Z; Chen SY; He Y; Zheng X; Zhao LD; Zhao WL; Wu W
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):112-117. PubMed ID: 36948864
[No Abstract] [Full Text] [Related]
32. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma.
Damron EP; Qazilbash MH; Fang PQ; Wu SY; Dabaja BS; Rondon G; Hosing C; Champlin RE; Bashir Q; Shpall EJ; Knafl MK; Lee HC; Manasanch EE; Patel K; Thomas SK; Orlowski RZ; Weber DM; Pinnix CC; Gunther JR
Transplant Cell Ther; 2023 Jan; 29(1):37.e1-37.e7. PubMed ID: 37753818
[TBL] [Abstract][Full Text] [Related]
33. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells.
Basak GW; Jaksic O; Koristek Z; Mikala G; Basic-Kinda S; Mayer J; Masszi T; Giebel S; Labar B; Wiktor-Jedrzejczak W;
Eur J Haematol; 2011 Jun; 86(6):488-95. PubMed ID: 21410533
[TBL] [Abstract][Full Text] [Related]
34. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma].
Yan S; Jin S; Wang PF; Yan LZ; Shang JJ; Shi XL; Wu XJ; Zhai YY; Yao WQ; Wang J; Yao Y; Fu CC
Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):819-825. PubMed ID: 37394852
[No Abstract] [Full Text] [Related]
36. Evaluation of mobilization efficacy with an extended interval following plerixafor administration.
Stump SE; Trepte M; Shaw JR; Grgic T; Ptachcinski JR; Sharf A; Riches M; Shea TC; Park YA; Alexander MD
J Oncol Pharm Pract; 2020 Oct; 26(7):1590-1597. PubMed ID: 32063103
[TBL] [Abstract][Full Text] [Related]
37. Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G-CSF in multiple myeloma: A pilot study.
Shastri A; Budhathoki A; Barta SK; Kornblum N; Derman O; Battini R; Raghupathy R; Verma AK; Frenette PS; Braunschweig I; Janakiram M
Am J Hematol; 2017 Oct; 92(10):1047-1051. PubMed ID: 28675459
[TBL] [Abstract][Full Text] [Related]
38. Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption.
Aggarwal V; Sabry W; Elemary M; Bosch M; Danyluk P; Mondal P; Stakiw J
Curr Oncol; 2021 Apr; 28(3):1571-1580. PubMed ID: 33922026
[TBL] [Abstract][Full Text] [Related]
39. Granulocyte colony-stimulating factor utilization postautologous hematopoietic stem cell transplant in multiple myeloma patients: Does one size fit all?
Jackson ER; Jared JR; Piccolo JK; Woo KM; Mably MS; Reed MP; Callander NS
J Oncol Pharm Pract; 2019 Jul; 25(5):1135-1141. PubMed ID: 29890920
[TBL] [Abstract][Full Text] [Related]
40. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
